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To enable detailed analyses of cell interactions in tumour development, new epithelial and mesenchymal cell lines were established
from human hepatocellular carcinoma by spontaneous outgrowth in culture. We obtained several hepatocarcinoma (HCC)-,
B-lymphoblastoid (BLC)-, and myofibroblastoid (MF)-lines from seven cases. In-depth characterisation included cell kinetics, genotype,
tumourigenicity, expression of cell-type specific markers, and proteome patterns. Many functions of the cells of origin were found to
be preserved. We studied the impact of the mesenchymal lines on hepatocarcinogenesis by in vitro assays. BLC- and MF-supernatants
strongly increased the DNA replication of premalignant hepatocytes. The stimulation by MF-lines was mainly attributed to HGF
secretion. In HCC-cells, MF-supernatant had only minor effects on cell growth but enhanced migration. MF-lines also stimulated
neoangiogenesis through vEGF release. BLC-supernatant dramatically induced death of HCC-cells, which could be largely abrogated
by preincubating the supernatant with TNFb-antiserum. Thus, the new cell lines reveal stage-specific stimulatory and inhibitory
interactions between mesenchymal and epithelial tumour cells. In conclusion, the new cell lines provide unique tools to analyse
essential components of the complex interplay between the microenvironment and the developing liver cancer, and to identify
factors affecting proliferation, migration and death of tumour cells, neoangiogenesis, and outgrowth of additional malignancy.
British Journal of Cancer (2008) 99, 151–159. doi:10.1038/sj.bjc.6604440 www.bjcancer.com
Published online 1 July 2008
& 2008 Cancer Research UK
Keywords: hepatocarcinogenesis; tumour stroma; epithelial–mesenchymal interactions
                                                         
Hepatocellular carcinomas are devastating cancers with increasing
worldwide incidence and mortality rates (Parkin et al, 2005). The
challenges posed by these often lethal cancers are daunting, with
conventional treatment options being limited. Chronic hepatitis
due to unresolved viral infections, excessive intake of ethanol, or
metabolic disorders has been identified as major risk factors
(Llovet et al, 2003; Farazi and DePinho, 2006). The viral infections
and other noxes usually result in cell damage, which evokes
inflammatory responses. The resulting chronic hepatitis and
associated fibrosis and cirrhosis are the major driving force for
the development of malignant liver cells (Ramadori and Saile,
2004; Bataller and Brenner, 2005; Robinson and Coussens, 2005;
Drucker et al, 2006).
The inflammatory response of the liver involves activation of
immune and other mesenchymal cells, such as endothelial and
stellate cells (Ramadori and Saile, 2004; Steiling et al, 2004;
Tuchweber et al, 2006). The latter ones play a leading role in the
development of fibrosis following their transition to myofibro-
blasts, which synthesise the main components of the extracellular
matrix. These different cell types release a plethora of growth
factors and proinflammatory mediators including cytokines and
reactive oxygen species, many of which are involved in growth
regulation of the epithelial cell compartment of the tissue. If release
of these signals is unbalanced and prolonged, selective growth of
(pre)malignant cells in the tissue may occur. This accelerates
tumour promotion and progression (Robinson and Coussens,
2005; Drucker et al, 2006). Therefore, the microenvironment
appears as a primary factor in determining whether dysfunctional
epithelial cells will continue to grow or not.
The gradual formation of liver cancer is accompanied by the
development of a specific tumour microenvironment, which is
composed of immune cells, small vessels, myofibroblastic cells,
and extracellular matrix components (Faouzi et al, 1999;
Bhowmick et al, 2004; Albini and Sporn, 2007). Tumour-associated
myofibroblasts are a rich source of extracellular matrix-degrading
proteases and of cytokines. They are, therefore, capable of
remodelling connective tissue, stimulate invasion, migration, and
growth of tumour cells, and induce neoangiogenesis (Dubuisson
et al, 2000; Monvoisin et al, 2002). Furthermore, important cellular
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leukocytes, including dendritic cells, natural killer cells, and
tumour-associated macrophages (Robinson and Coussens, 2005;
De Visser et al, 2006; Whiteside, 2006). Their interaction with
tumour cells often results in immunotolerance through reduced
immunogenicitiy of the tumour and incapacitation of immune
cells. The immune cells may even increase the potential of cancer
cells to progress, proliferate, and metastasise, that is, the tumour-
associated macrophages release metalloproteinases for local tissue
destruction and interleukin (IL)-6 and IL-8 for endothelial cell
invasion into the tumour (De Visser et al, 2006; Whiteside, 2006).
In summary, there is strong evidence that the various
mesenchymal cell types in the (pre)malignant tissue undergo
a multiplicity of deviations, crucial for cancer formation,
progression, and maintenance.
However, the precise role of specific mesenchymal cells and
secreted factors during the stepwise development of liver cancer is
still largely unknown. Detailed pertinent studies are hampered by
the paucity of well-defined human cell lines. The most commonly
used hepatic epithelial lines are HepG2 and Hep3B deriving from
human hepatoblastoma and hepatocellular carcinoma, WRL68
from a human embryonal liver, and CCL13 Chang liver cells, with
no available information on the source and with reported
contamination by Hela-cells (www.atc.org). As the lines have been
isolated decades ago, a huge number of diverse subclones exist that
notoriously produce heterogeneous and sometimes conflicting
data. Hardly any information is available on some of the more
recently established hepatocellular carcinoma lines (Saito et al,
1989; Park et al, 1995; Li et al, 2003; Hu et al, 2004). A few hepatic
mesenchymal lines from human liver or liver tumours have been
isolated. Similar to the existing epithelial cells, these mesenchymal
lines appear to be barely authenticated, ill characterised and
standardised (Arthur 1996; Xu et al, 2005).
In this study, epithelial and two types of mesenchymal cell lines
were reproducibly isolated from human hepatocarcinomas
(HCCs). Mesenchymal cells were identified as B-lymphoblastoid
(BLC)- and myofibroblastoid (MF)-cells, reflecting two of the key
cellular constituents of the microenvironment in liver tumours.
Extensive characterisation revealed that these new lines have
retained many biological and functional characteristics of the cells
of origin. We found that all of the mesenchymal cell lines
dramatically enhance growth of liver cancer prestages in an in
vitro model. This may partially explain the fact that HCCs
frequently arise multifocally (Llovet et al, 2003; Farazi and
DePinho, 2006). In advanced stages, MF-cells stimulate cell
migration and neoangiogenesis. Interestingly, the BLC-lines induce
death of HCC-cells, apparently through TNFb secretion. This
observation may be of interest from a therapeutic point of view. In
conclusion, the new cell lines reveal stage-specific stimulatory and
inhibitory interactions between mesenchymal and epithelial
tumour cells. They offer new tools to unravel the mechanistic role
of the microenvironment during hepatocarcinogenesis.
MATERIALS AND METHODS
Establishment of cell lines
Patients with primary liver tumours were subjected to surgical
resection. A fully documented patient’s history and informed
consent were obtained in each case (see also online Supplementary
material). The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki, as reflected by the approval of the
‘Ethic Committee of the Vienna Medical University’. Tumour
samples were fixed and processed as described (Raidl et al, 2004).
Additional samples were transferred into transport medium
(RPMI1640; Sigma, St Louis, MO) containing 10% FCS
(PAA, Linz, Austria), 100Uml
 1 penicillin-streptomycin
(PAA), 2.5mgml
 1 fungizone (Sigma) and 100mgml
 1 gentamycin
(Biochrom AG, Berlin, FRG). The establishment of cell lines
followed published protocols (Frazier et al, 1990; Park et al, 1995).
In brief, tumour tissue was cut into pieces of approximately
0.5mm
3, which were incubated in ACL4-medium and 5% FCS at
371C and 5% CO2. Outgrowing semi-adherent cells were separated
and cultivated. Fibroblasts disappeared after approximately 13
weeks, were overgrown by tumour cells, or eliminated by
differential trypsinization. Established cell lines were maintained
in RPMI1640 and 10% FCS (HCC- and BLC-lines) or ACL4-
medium and 5% FCS (MF-lines). Cells were regularly tested by the
Mycoplasma Detection Kit (Roche, Mannheim, FRG).
Treatment with conditioned supernatant
Control media: standard medium of indicator cells (50% v/v) and
unconditioned medium routinely used for the cells tested (50% v/v).
Treatment: standard medium of indicator cells (50% v/v) and
medium conditioned for 72h by the cells tested (50% v/v).
Immunoneutralisation: medium or conditioned supernatants were
pre-incubated with neutralising antibodies (see online Supple-
mentary material) at 371C for 60min.
Tumourigenicity
Using three animals per cell line, 2 10
6 cells in 100ml of 0.9%
NaCl were subcutaneously injected into SCID/BALB/c mice.
Tumour formation was viewed periodically by palpation (Gotz-
mann et al, 2002). Formalin-fixed and paraffin-embedded sections
of xenocrafts were stained with hematoxylin–eosin. The experi-
ments were approved by the ‘Committee of Animal Protection of
the Austrian Ministry of Sciences’ and performed according to
Austrian regulations, which agree with the criteria outlined in the
‘UKCCCR Guidelines for the Welfare of Animals in Experimental
Neoplasia’ in 1998.
Karyotyping, fluorescence in situ hybridisation (FISH) and
comparative genomic hybridisation (CGH) of the cell lines were
performed as described previously (Raidl et al, 2004; Streubel et al,
2006).
Sequencing
Exons 2 and 3 of Ras-protoncogenes were sequenced, as given
elsewhere (Macheiner et al, 2006). For the primers applied see
Supplementary material.
Telomeric repeat amplification protocol-assay
Telomeric repeat amplification protocol-assay followed the recent
descriptions (Kim and Wu, 1997). Amplification products were
separated by PAGE and visualised by FluorImager-595 (Molecular-
Dynamics, Sunnyvale, CA, USA). One total product generated
(TPG) corresponds to 600 molecules of telomere substrate primers
extended by at least four telomeric repeats within 30min at 301C.
TPGs were calculated per cell, based on protein amount and cell
numbers applied. Data were derived from 2–4 experiments.
Immunodetection
For primary antibodies and ELISA-kits used see Supplementary
material. For immunohistology, cells were processed as described
recently (Gotzmann et al, 2002; Drucker et al, 2006). Immunor-
eactions were visualised by application of cye-dye-conjugated
secondary antibodies and TCS-SP confocal microscopy (Leica,
Heidelberg, FRG). Detailed discription of FACS analyses of the
semi-adherent cell lines and antisera applied are given elsewhere
(Pfistershammer et al, 2004; Bluml et al, 2005). ELISA-kits were
applied according to the manufacturers’ instructions.
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SPF Wistar rats, obtained from and kept at the ‘Division for
Decentralized Biomedical Facilities Vienna’, received 250mg of
N-nitrosomorpholine per kilogram body weight by gavage to induce
the formation of preneoplastic hepatocytes. Twenty-one days later
livers were perfused with collagenase. The cell suspension obtained
was purified from mesenchymal cells and seeded on collagen-coated
Petri dishes. For further details see Drucker et al, 2006.
DNA content and DNA replication
For autoradiography newly synthesised DNA was labelled with
3H-thymidine (60–80Cimmol
 1; ARC, St Louis, MO), which was
added at 0.5mCiml
 1 medium 24h before harvesting. For further
processing see Drucker et al, 2006.
RT PCR
Total RNA was extracted and transcribed, as described (Drucker
et al, 2006). For primers used see Supplementary material. PCR
products were separated in 1.2% agarose gels, stained with
ethidium bromide, and visualised by UV-light. Viral DNA of
Epstein-Barr-virus (EBV) was detected as given elsewhere (Bauer
et al, 2005; Drucker et al, 2006).
Proteomics
Cells were incubated with
35S-methionine for 6h for metabolic
labelling of proteins synthesised within this period. The cell
supernatant (secretome) was processed and subjected to two-
dimensional (2D) gel electrophoresis and subsequent autoradio-
graphy. Fluorescent intensities of cytosolic protein spots on 2D-
gels were normalised to the intensities of b-actin to determine
relative amounts. Spots were selected for protein identification by
mass spectrometry. For details see Zwickl et al, 2005.
Human umbilical vein endothelial cells
Human umbilical vein endothelial cells (HUVEC) were isolated
from umbilical cords by approved protocols (Jaffe et al, 1973) and
kept on fibronectin-coated plates (Chemicon, Hampshire, UK) in
M199-medium with 20% FCS (GibcoBRL, Grand Island, NY) and
10mg of endothelial cell growth supplement (ECGS, Upstate-
Biotechnology, NY) per ml at 371Ci n5 %C O 2. Cells were used after
3–6 passages.
RESULTS
Establishment and characterisation of cell lines
Specimens from six hepatocellular carcinomas and one undiffer-
entiated primary liver tumour were transferred to culture.
Generally, outgrowth of big, semiadherent aggregates occurred
after approximately 7 weeks (Figure 1B). About 6 weeks later, cells
appeared exhibiting epithelial (Figure 1A) or myofibroblastoid-like
morphology (Figure 1C).
Epithelial cells (HCC-lines) Many functions of the cells of origin
were found to be preserved. We determined deviations from the
normal genotype by CGH. Frequency and pattern of alterations in
the lines highly resembled those recently found in human
hepatocellular carcinoma (Figure 2; Raidl et al, 2004). Gains of
DNA clustered in chromosome arms 7q, 8q, 12q, and 20p and
losses were often found at 4q, 6q, 8p, 9p, and 13q. We also
sequenced the hotspots of Ki-Ras, Ha-Ras, and N-Ras. No
mutations could be found in any of the four lines, which reflects
a further characteristic feature of liver cancer (Llovet et al, 2003;
Stahl et al, 2005; Farazi and DePinho, 2006). Despite of multiple
genetic alterations in the CGH analysis the tumourigenicity of the
lines was weak. Two of the cell lines formed tumours in one of
three inoculated mice only (Table 1).
The HCC-lines were positive for the epithelial marker proteins
cytokeratin 8 and 18 and expressed the glycolysis enzyme lactate
dehydrogenase, which is a feature common to most cultured
tumour cells (Figure 1). To study the secretome of the HCC-lines
we applied a novel proteomics approach, which is based on
metabolic labelling of secreted proteins (Zwickl et al, 2005). All cell
lines release hepatocyte-specific proteins, such as albumin,
a1-antitrypsin, serotransferrin, and apolipoprotein A1 and E to
the medium. Furthermore, they secrete a complement cytolysis
inhibitor, a characteristics of tumour cells. The level of
a-fetoprotein in the secretome was low in three of the four lines
investigated, which reflects the features of the corresponding liver
tumour (Table 1 and online Supplementary material).
A hallmark of hepatocytes is their versatility to bioactivate
diverse toxic chemicals. Accordingly, the cell lines express phase-I
(cytochrome-P450 1A1, 1B1, 3A4, and 2E1) and phase-II enzymes
(glutathione-S-transferase and sulfotransferase 1A1) at levels
similar to human liver (data not shown). Enzymes coping with
reactive oxygen species, such as superoxide dismutases and
catalase, were expressed as well (Table 1).
Detailed comparison of the genotype and the expression of liver-
specific proteins of the new HCC-lines and of the already
established HepG2- and Hep3B-cells are given as online Supple-
mentary material. The new lines appear to have retained more
features of hepatocytes than the already established cell lines.
Semi-adherent cells (BLC-lines) These lines contained parts of the
EBV genome at a mean load of approximately 25 copies per cell.
Considering the genomic alterations detected by the cytogenetic
methods, they revealed much less deviations than the HCC-cell
lines. The line BLC-4 revealed gains of 12q24.1-ter and an
elongated 9p, indicating that additional genetic material from
12q24.1-ter was translocated to the short arm of chromosome 9
(Figure 2B). BLC-7 harboured additional chromosomes 9, 12, and
14. The karyotypes of the two further cell lines showed no
aberrations. FISH for the chromosomal regions coding for
immunoglobulin heavy chains (14q32) revealed no translocation
in all cells studied. Furthermore, lines were found to be
monoclonal as determined by the rearrangement pattern in the
IgG-locus (Table 1). In SCID mice all cell lines tested (BLC-1, -2,
and -4) produced anaplastic tumours exhibiting vast areas of
necrosis and frequent mitosis.
The BLC-lines revealed a lymphoblastoid phenotype with many
features of activated B-cells, as examined by FACS analyses
(Table 1). The cells also displayed some characteristics of activated
T-cells, which may be due to their infection with EBV. FITC-
labelled latex beads were taken up by the majority of the cells.
Upon stimulation with PMA or LPS they released superoxide to the
medium. Thus, the cell lines highly resemble B-cells, and exhibited
some features known from macrophages such as phagocytosis and
superoxide-production (Table 1; Parzefall et al, 2001; Teufelhofer
et al, 2003).
Myofibroblastoid cells (MF-lines) These cell lines are charac-
terised by a population doubling time of more than 150h and a
barely detectable telomerase activity (Table 1). They exhibited minor
genetic changes. Loss of genetic material in 4q and 6p was evident in
two of the lines investigated (MF-2 and MF-6). No tumourigenicity in
SCID mice was observed with any of the MF-lines.
The cell lines expressed considerable amounts of various
microfilaments, such as a-smooth muscle actin, fibulin-2, tenascin,
and vimentin and, therefore, meet the main characteristics of
myofibroblasts. The expression of the junctional proteins plako-
globin and N-cadherin, as observed in the MF-lines, has been
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Figure 1 Morphology and proteome pattern differing in hepatocarcinoma, B-lymphoblastoid, and myofibroblastoid cell-lines. Light microscopy of HCC-
1.2 in (A), BLC-1 in (B), and MF-2 cells in (C). Arrow in (C) indicates lipid droplets. Magnification:  80. In (D–F) cytosolic proteins of the lines were
separated by 2D-PAGE and detected by fluorography. Selected proteins were further identified by mass spectrometry (Zwickl et al, 2005). A segment of a
representative 2D-PAGE gives highly different protein profiles in (D) HCC-1.2, in (E) BLC-2, and in (F) MF-2 cells. Swiss Prot numbers: P05783, keratin type
1, cytoskeletal 18; P09936, ubiquitin carboxyl-terminal hydrolase isozyme L1; P40261, nicotinamide N-methyltransferase; and P52566, rho GDP-dissociation
inhibitor 2.
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Figure 2 Genomic alterations in hepatocarcinoma and B-lymphoblastoid cells. In (A) relative frequencies of chromosomal alterations in HCC-1.1,
HCC-1.2, HCC-2, and HCC-3, as analysed by CGH. Columns give percentage of lines with gains or losses of DNA on the chromosomal arms indicated. In
(B) cytogenetic analyses of BLC-4: (a) G-banding reveals elongation of 9p (arrow); (b) blue line indicates the green to red fluorescence ratio profile of
chromosome 12. The grey lines give the 95% confidence interval. Green bar besides the chromosome ideogram indicates a gain on 12q (arrow). (c) FISH for
chromosome 9 (green) shows that the additional material on 9p is chromosome 9-negative. (d) FISH for the immunoglobin heavy chain region
demonstrates normal signals on chromosome 14.
Cell interaction and hepatocarcinogenesis
S Sagmeister et al
154
British Journal of Cancer (2008) 99(1), 151–159 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sTable 1 Characterisation of cell lines
Epithelial cell lines (HCC-1.1, HCC-1.2, HCC-2, and HCC-3)
Population doubling time 37.3–46h Detoxification
Cytochromes P4501A1, 1B1, 3A4, and 2E1, Sulfotransferase 1A1
b,c,h,j ++
Telomerase activity
a 18–65 TPG Aldehyde dehydrogenase
Liver carboxylesterase 1, Glutathione-S-transferase
b +
Tumourigenicity +/  Antioxidation
CuZn Superoxide dismutase, Mn Superoxide dismutase
b ++
Epithelial/Hepatocyte markers
Albumin, a1-Antitrypsin, Fibrinogen g-chain,
Apolipoprotein E, Cytokeratin 18
b,j,k ++
Thioredoxin, Catalase
b,c +
Cytokeratin 8, Fatty acid binding protein liver-type,
Serotransferrin, Apolipoprotein A1, Haptoglobin
b,j,k +
Other proteins
Lactat dehydrogenase, Complement cytolysis inhibitor
b ++
a-Fetoprotein
b +/  Vitamin D binding protein, Enoyl-CoA hydratase
b +
Secretion of cytokines
IL-1b, IL-4, IL-5, TNFa, TNFb
d  
Neoangiogenesis
Secretion of vEGF (B1000)
d ++
Non-adherent cell lines (BLC-1, BLC-2, BLC-4, BLC-6, and BLC-7)
Population doubling time 19–23h Myeloic cell markers
CD13, CD14, CD15, CD16, CD25, CD33 CD36, CD38,
CD64, Myeloperoxidase
e  
Telomerase activity
a 6.1 16 TPG Superoxide production
f ++
Tumourigenicity ++ Phagocytosis
Uptake of latex beads
f +
Leukocyte marker
CD45
e ++
Phagocytic glycoprotein I (CD44), MHCI, MHCII
e +
B-cell marker
CD19
e ++
Secretion of cytokines
IL-6 (B3000), IFNa (B70), TGFb1( B1000), TNFa
(B200),TNFb (B1000)
d ++
Progenitor B-cell marker
CD10
e  
IL-1b, IL-4, IL-5
d  
Activated B-cell markers
CD23, B7H1
e ++
TNF/TNFR-system
CD40
e +
B-CLL marker
CD5
e  
CD40L
b, CD95L (FAS-L)
e,d  
T-cell markers
CD1a, CD3, CD4, CD8
e  
Further proteins
Rho GDP-dissociation inhibitor 2
b,k,l +
T-lymphocyte activation antigens
CD80, CD86
e +
Hematopoietic lineage cell-specific protein, Coronin 1a, Gelsolin,
Coactosin, I-Plastin
b,l +
T-cell surface glycoprotein E2
CD99
e +
Monoclonality
i +
Dendritic cell markers
Langerin, bdca3, bdca4
e  
Myofibroblastoid cell lines (MF-1, MF-2, MF-3, MF-5, and MF-6)
Population doubling time 181–267h Epithelial markers
Cytokeratin 7 and 8 (Cam 5.2) Cytokeratin 8 and 18
g  
Telomerase activity
a o2 TPG Endothelial markers
ICAM1 (cd54), Von Willebrand Factor, PECAM1 (cd31)
g  
Comparative genomic hybridisation Loss in 4q,
6p, 13q
Growth factors
Hepatocyte growth factor, Keratinocyte growth factor
c +
Tumourigenicity  
 
Myofibroblast markers
Tenascin
c ++
Further proteins
Integrin a2, Integrin aV, Matrix metalloproteinase 14, Transgelin
b +
a-Smooth muscle actin, Fibulin-2 Vimentin
c,g ++ Gelsolin, Cofilin, Ezrin
b,l +
Plakoglobin, N-Cadherin
g + Nicotinamide N-methyltransferase, Ubiquitin
carboxyl-terminal hydrolase isozyme L1,
Collagen a type 1,2, and 3; Fibronectin
b,j,l
+
Secretion of cytokines
IL-1b, IL-4, IL-5, TNFa, TNFb
d  
Data are given if at least 2 of the cell lines were investigated and if all of the lines investigated showed identical features. ( ), negative; (+/ ), weakly positive; (+), positive; (++),
strongly positive.
aTelomerase activity gives the mean TPG unit per cell. Determined by:
b2D PAGE/MS.
cRT PCR.
dELISA; number in parentheses gives concentration of
cytokine in pgml
 1 medium.
eFACS analyses according to (Pfistershammer et al, 2004; Bluml et al, 2005).
fMethods described in (Parzefall et al, 2001; Teufelhofer et al, 2003).
gImmunoflourescence.
hQuantitative RT PCR.
iCharacterisation of the rearrangement pattern of the IgG locus, as described in (Wan et al, 1990). Not expressed in:
jBLC-cells.
kMF-cells.
lHCC-cells.
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myofibroblasts and in stellate cell lines (Vogel et al, 2000; Proell
et al, 2005; Xu et al, 2005). Their proteome pattern differed largely
from that of the HCC- and BLC-cells (Table 1; Figure 1).
Interactions between epithelial and mesenchymal cells in
early and advanced stages of hepatocarcinogenesis
B-lymphoblastoid and myofibroblastoid cells stimulate growth of
early stages of hepatocarcinogenesis To study the impact of
mesenchymal cells on the development of liver tumours, we
applied a recently developed ex vivo culture model as a screening
tool (Drucker et al, 2006). Due to the lack of reliable markers and
culture models for human liver cancer prestages this system uses
premalignant rat hepatocytes, which are detectable by their
selective expression of placental glutathione-S-transferase (GSTp-
pos). GSTp-pos cells show an approximately fourfold higher
probability for DNA replication than unaltered (GSTp-neg) cells
indicating an inherent growth advantage, the main characteristic
of precancerous cells (Figure 3). Incubation with the supernatant
of BLC- or MF-cells raised DNA replication and DNA content of
primary hepatocytes (Figure 3). When discriminating between
unaltered and premalignant hepatocytes, the highest induction of
DNA synthesis occurred in the premalignant, GSTp-pos cells by
supernatant of MF-6, followed by supernatant of MF-2, BLC-6, and
BLC-2. Fourty percent of GSTp-pos hepatocytes were stimulated
by factors released by MF-6 to replicate DNA, which is remarkably
high for hepatocytes in primary culture. The effect of MF-2 and
MF-6 supernatant could be largely abrogated by pre-incubation
with neutralising anti-HGF (Figure 3B), whereas anti-HGF was
without effect on the BLC-supernatant (data not shown). Thus,
HGF appears to be the main growth stimulator released by the
MF-cells, whereas the growth-inducing component in the BLC-
supernatants remains to be identified. In conclusion, the factors
released by the two different mesenchymal cell types appear to
stimulate preferential outgrowth of tumour prestages.
B-lymphoblastoid cells induce death of hepatocarcinoma cells The
HCC-2, BLC-2, and MF-2 cell lines were all isolated from the same
donor and were, therefore, chosen to study interactions between
the different cell types in liver cancer. Supernatant of MF-2 had
minor effects on number, replication, and death of HCC-2 and also
of other hepatocarcinoma cell lines (data not shown). However,
BLC-2 supernatant induced dramatically cell death in HCC-2
cultures (Figure 4A). In parallel, a slightly reduced fraction of cells
in S-phase was evident (Figure 4A). Accordingly, after 4 days of
treatment cell numbers were only approximately 15% of controls
(Figure 4B). A similar effect was also seen when treating HCC-1.2,
HCC-3, or HepG2 cells with supernatant conditioned by BLC-1, -4
and -7 (data not shown).
The BLC lines secrete considerable amounts of TNFb (Table 1).
The cytocidal effect of the cells could be simulated by treating
HCC-2 with TNFb at a concentration being equivalent to that in
the BLC-supernatant. When TNFb-containing medium or BLC-2
supernatant were preincubated with neutralising TNFb-antiserum,
the effect of recombinant TNFb was blocked completely and of the
BLC-2 supernatant incompletely (Figure 4A and 4B). This indicates
that additional factors may be involved in the tumouricidal effects
of the BLC cells.
Myofibroblastoid cells produce angiogenic factors and increase
migration of hepatocarcinoma cells We hypothesised that super-
natants from MF-lines could stimulate tumour progression by
enhancing neoangiogenesis and migration of hepatocarcinoma
cells. In fact, MF-cells produce angiogenic factors, as reflected by
an increased size of HUVEC colonies (Figure 4C). Antibodies
neutralising vascular endothelial growth factor (vEGF) largely
blocked colony growth of the endothelial cells indicating that vEGF
is the main angiogenic factor secreted by the lines. Also HCC-cells
release considerable amounts of vEGF, as determined by the
HUVEC-assay (data not shown) and by ELISA (Table 1).
To determine the effects of MF-cells on the migratory capability
of HCC-cells, we performed scratch assays (Figure 4D). Medium
conditioned by MF-2 cells significantly accelerated scratch closure
rates in HCC-2 cultures when compared to control medium.
Similar results were obtained when treating HCC-1.2 lines with
MF-6 derived supernatant (data not shown). This indicates that
MF-cells increase considerably the ability of hepatocarcinoma cells
for migration.
DISCUSSION
The present work describes the establishment of several hepato-
cellular, B-lymphoblastoid and myofibroblastoid cell lines from
human hepatocellular carcinoma and provides mechanistic
explanations for their complex interactions at different stages of
hepatocarcinogenesis (Figure 5).
Each of the three types of cell line represents a distinct cellular
identity, as determined by advanced techniques. CGH revealed that
the epithelial HCC-cells show a profile of genomic alterations,
which differs clearly from that of the BLC- and the MF-lines. We
also studied the proteome and applied a novel method to
discriminate between intracellular and secreted proteins (Zwickl
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cytes. Treatment of hepatocytes commenced 4h after seeding and lasted
for 68h. Abbreviations of treatment groups: (Co), control medium; (BLC-
2) or (BLC-6), medium supernatant conditioned by BLC-2 or BLC-6; (MF-
2) or (MF-6), medium supernatant conditioned by MF-2 or MF-6 cells;
(HGF), aliquots of a HGF stock solution (Sigma-Aldrich; 20mgml
 1 PBS/
0.1% BSA) were added for finally 20ngml
 1 medium; (HGFþAB), (MF-
2þAB), or (MF-6þAB), HGF-containing medium or conditioned super-
natants were pre-incubated with anti-HGF. In (A) and (B):
3H-thymidine
was added 24h before harvesting. DNA synthesis was determined by
autoradiography. In each experiment 2000 nuclei of GSTp-neg cells and
600 nuclei of GSTp-pos cells were evaluated per treatment group. The
labelling index (LI%) was calculated as percentage of labelled hepatocyte
nuclei per total number of hepatocyte nuclei counted. Columns: LI (%) of
replicating GSTp-neg (&) and GSTp-pos (’) hepatocytes. Means±s.e.m.
of at least three separate liver cell preparations are given. Statistics by
Kruskal–Wallis test: Co vs cell supernatant or HGF: (a) Po0.05; (b)
Po0.01; cell supernatant vs neutralised supernatant or HGF vs neutralised
HGF: (c) Po0.05.
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set al, 2005). We found that all line types studied exhibit a
characteristic and cell-type specific proteome and secretome
pattern. Furthermore, most of the HCC-cell lines have maintained
features characteristic for hepatocytes and secrete albumin,
serotransferrin, and the g-chain of fibrinogen. The proteome
pattern also revealed considerable expression of various enzymes
metabolising drugs, aldehydes or reactive oxygen species (Table 1).
Accordingly, the HCC lines have been shown to bioactivate diverse
genotoxic compounds, such as polycyclic hydrocarbons, aflatoxin
B1, and nitrosamines (Winter et al, submitted). Thus, the new
HCC-cell lines exhibit a capability for drug-metabolism similar to
the tissue of origin.
The BLC-lines highly resemble B-cells, exhibit also some
features known from macrophages, and contain several copies of
the EBV-genome per cell. All our donors harboured a chronic,
subclinical EBV-infection, according to a rate of approximately
95% EBV-carriers in the European population (Herrmann and
Niedobitek, 2003). The virus immortalises the infected cells to
proliferate indefinitely in culture most probably by inducing
autocrine loops of TNFa, TNFb, and IL-10 (Rochford et al, 1997).
Our EBV-positive BLC-cells produce high levels of TNFb, IL-6, and
TGFb1 and variable levels of TNFa. In addition, two of the four
lines appeared transformed with gross karyotypic abnormalities
(Figure 2). It is presently unclear whether these genomic
aberrations were caused by the EBV in the donor or occurred
during establishment of the lines in vitro.
Hepatocellular carcinoma were reported to recruit and activate
hepatic stellate cells or portal fibroblasts to tumour-associated
myofibroblasts (Faouzi et al, 1999). The transdifferentiation of
fibroblasts into myofibroblasts is modulated by cancer cell-derived
cytokines, such as TGFb (Bieri and Moses, 2006). The MF-lines
established from the hepatocellular carcinoma meet many
characteristics of hepatic stellate cells activated to tumour-
associated myofibroblasts. They express a-smooth muscle actin,
fibulin-2, vimentin, and the junctional proteins plakoglobin and N-
cadherin as recently described for activated stellate stells (Vogel
et al, 2000; Monvoisin et al, 2002; Steiling et al, 2004; Proell et al,
2005; Tuchweber et al, 2006). Furthermore, the MF-cells contain
lipid droplets, which highly resemble the cytoplasmic storage site
for retinyl ester in stellate cells (Figure 1C). All these features
together suggest that the MF-lines rather derive from stellate cells
than from portal fibroblasts.
Cell–cell interactions have a major impact on carcinogenesis in
the liver and other organs (Albini and Sporn, 2007). Along these
lines, we recently found that DNA synthesis of premalignant
hepatocytes is increased by growth factors released from Kupffer
and endothelial cells of normal liver (Drucker et al, 2006). The
present work shows that cancer-derived mesenchymal cells also
stimulate growth of premalignant hepatocytes (Figure 5). The new
BLC cell lines produce TNFa, TNFb, TGFb1, IL-6, and presumably
IL-10 (Table 1; Rochford et al, 1997). In recent studies, TNFa and
IL-6 had no impact on DNA replication of premalignant
hepatocytes, whereas TGFb1 even suppressed the growth (Lo ¨w-
Baselli et al, 2000; Drucker et al, 2006). In this work, 0.7 or 1ng of
TNFbml
 1 medium lowered DNA-replication of hepatocytes in
primary culture by 57 and 76%, respectively (data not shown). IL-
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s10 has been described to exert anti-inflammatory and cytoprotec-
tive effects in the liver and to exert minor effects on hepatocyte
replication (Louis et al, 1998). Thus, the factors responsible for the
pronounced growth stimulation of the first stages of hepato-
carcinogenesis by the BLC-lines remain to be identified.
It is controversially discussed whether the latent EBV infection
accelerates the onset of HCC by supporting HCV replication,
exacerbating the inflammatory processes in the liver, or by direct
growth stimulation of the tumour cells (Sugawara et al, 1999;
Herrmann and Niedobitek, 2003). In any case, tumour-associated
immune cells are often localised close to the border of the tumour.
It, therefore, appears likely that the cytokines released by the BLC-
cells act on both, the tumour itself and on the tumour prestages in
the vicinity (Ramadori and Saile, 2004; Drucker et al, 2006). Thus,
the EBV infection may stimulate B-cells to promote carcinogenesis
by enhancing outgrowth of the tumour prestages. This may
contribute to the fact that HCCs often arise multifocally, which
complicates therapy and worsens prognosis.
In contrast to the effects on premalignant hepatocytes, BLC-
supernatant exerted a pronounced tumouricidal effect in the
HCC-cells (Figure 5), and other cell lines tested, such as HepG2-
Hep3B-, MCF7-, and CRL2020-cells (data not shown). One
candidate cytokine is TNFb, which is secreted by all our BLC-
lines. As a prototypical member of the TNF-superfamily, it induces
death of a wide range of tumour cells, which is based on activation
of the immune system and on direct killing of tumour cells
expressing the appropriate TNF-receptors (Strand et al, 1996;
Tamada and Chen, 2006). Under our conditions recombinant
TNFb simulates partly the effects of the BLC-supernatant implying
that additional factors may be involved. TNFa has sequence
homologies to TNFb and exerts similar biological properties
(Tamada and Chen, 2006). However, only two of the BLC-lines
expressed this cytokine, although all lines are capable of inducing
cell death. Further examples for tumouricidal effects through
members of the TNF-superfamily are the cd40/cd40l(cd154)- and
the cd95/cd95l-systems (Strand et al, 1996; Tamada and Chen,
2006). However, our BLC-cells were positive for cd40 but negative
for cd40l and cd95l, indicating that these death-inducing systems
are not operative in the BLC-supernatant. Although being
detrimental to tumour cells, the EBV-DNA load in hepatocellular
carcinoma was found to be 1000-fold higher than in peripheral
blood mononuclear cells (Sugawara et al, 2000; Tamada and Chen,
2006). It appears possible that the tumour controls and inactivates
these cells, as described for other infiltrating leukocytes (De Visser
et al, 2006; Whiteside, 2006).
Myofibroblasts are a rich source of growth factors, including
TGFb1, platelet-derived growth factor, FGF2, FGF7, HGF, and others
(Monvoisin et al, 2002; Ramadori and Saile, 2004; Steiling et al,2 0 0 4 ;
Bataller and Brenner, 2005). We recently found that the addition of
FGF7 or HGF to the medium dramatically raises replication of
premalignant hepatocytes, which may explain the growth stimulatory
effect of the MF-supernatant on the GSTp-pos hepatocytes and the
abrogation of this effect by neutralising anti-HGF antibodies in this
study (Drucker et al, 2006; Abb.3). Thus, this cell type may also
contribute to the outgrowth of additional malignancy within the
liver. In advanced stages of hepatocarcinogenesis, the effects of the
MF-cells appear to be different from growth stimulation (Figure 5).
They synthesise considerable amounts of vEGF for neoangiogenesis
and increase the motility of the HCC-cells (Figure 4). We could not
obtain any evidence regarding the fact that the increased migration
of the HCC-lines by the MF-derived supernatant was due to HGF or
FGF7 (data not shown).
In conclusion, the immune cells and myofibroblasts, derived
from hepatocellular carcinoma, release a plethora of cytokines that
act on both, the tumour itself and on tumour prestages. Thus, the
new cell lines described in the present work are a unique tool to
unravel the complex functional interplay of epithelial cells and the
microenvironment at different stages of liver cancer development.
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